These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36226408)

  • 41. Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
    Stephens JM; Bensink M; Bowers C; Hollenbeak CS
    Curr Med Res Opin; 2019 Feb; 35(2):229-240. PubMed ID: 29661043
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens.
    Zardawi SJ; Nordman I; Zdenkowski N
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1266. PubMed ID: 32761893
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
    Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
    Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia.
    Frampton JE; Faulds D
    Pharmacoeconomics; 1996 Jan; 9(1):76-96. PubMed ID: 10161371
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy.
    Scott SD; Chrischilles EA; Link BK; Delgado DJ; Fridman M; Stolshek BS
    J Manag Care Pharm; 2003; 9(2 Suppl):15-21. PubMed ID: 14613340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical study on safety and efficacy of JiSaiXin (recombinant human granulocyte colony stimulating factor injection manufactured in China) for Chinese undergoing chemotherapy.
    Wang L; Huang XE
    Asian Pac J Cancer Prev; 2015; 16(1):299-301. PubMed ID: 25640368
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Continuous Intravenous Administration of Granulocyte-Colony-Stimulating Factors-A Breakthrough in the Treatment of Cancer Patients with Febrile Neutropenia.
    Căinap C; Cetean-Gheorghe S; Pop LA; Leucuta DC; Piciu D; Mester A; Vlad C; Ovidiu C; Gherman A; Crişan C; Bereanu A; Bălăcescu O; Constantin AM; Dicu I; Bălăcescu L; Stan A; Achimaş-Cadariu P; Căinap S
    Medicina (Kaunas); 2021 Jun; 57(7):. PubMed ID: 34208815
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biosimilar pegfilgrastim and adherence to guidelines for chemotherapy-induced neutropenia and infections in cancer patients.
    Danova M; Antonuzzo A; Spandonaro F; Pronzato P
    Infez Med; 2020 Mar; 28(1):127-129. PubMed ID: 32172272
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
    Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
    Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and Safety of Lipegfilgrastim in Lung Cancer Patients Receiving Myelosuppressive Chemotherapy in a Real-World Setting: Results of an Analysis of Pooled Data from Two Non-Interventional European Studies.
    Gessner C; Potthoff K; Frost N
    Oncol Res Treat; 2021; 44(3):93-102. PubMed ID: 33477145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
    Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
    Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
    Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
    Biganzoli L; Untch M; Skacel T; Pico JL
    Semin Oncol; 2004 Jun; 31(3 Suppl 8):27-34. PubMed ID: 15181606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.
    Mahtani RL; Belani R; Crawford J; Dale D; DeCosta L; Gawade PL; Huynh C; Lawrence T; Lewis S; MacLaughlin WW; Narang M; Rifkin R
    Support Care Cancer; 2022 Jul; 30(7):6135-6144. PubMed ID: 35426046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.
    Weycker D; Barron R; Edelsberg J; Kartashov A; Legg J; Glass AG
    BMC Health Serv Res; 2014 Apr; 14():189. PubMed ID: 24767095
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
    Cooper KL; Madan J; Whyte S; Stevenson MD; Akehurst RL
    BMC Cancer; 2011 Sep; 11():404. PubMed ID: 21943360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors.
    Tomic K; Long S; Li X; Fu AC; Yu TC; Barron R
    J Oncol Pharm Pract; 2013 Dec; 19(4):328-37. PubMed ID: 23353712
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
    Aapro M; Boccia R; Leonard R; Camps C; Campone M; Choquet S; Danova M; Glaspy J; Hus I; Link H; Sliwa T; Tesch H; Valero V
    Support Care Cancer; 2017 Nov; 25(11):3295-3304. PubMed ID: 28842778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.